Sign up
Pharma Capital

Coherus BioSciences earns Baird upgrade after sales of its flagship drug comfortably exceed expectations

Sales of its drug Udenyca are expected to be between $36 million and $38 million for the fiscal first quarter
White blood cells gathering
Udenyca is a biosimilar that stimulates white blood cell growth in patients who have received cancer medications

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares surged after announcing late Friday that preliminary sales of its drug Udenyca are expected to be between $36 million and $38 million for the fiscal first quarter.

Investors injected new life into the stock, boosting the share price 6.9% to $15.49.

Its sales performance caught the attention of Baird analyst Michael Ulz, who reiterated the firm’s Outperform rating and its price target of $28 for Coherus on Monday.

Udenyca is a biosimilar that stimulates white blood cell growth in patients who have received cancer medications. The consensus estimate for its quarterly sales was a $3.9 million, which the drugmaker wildly exceeded.

Baird’s own estimate was even lower at $2.8 million.

The Redwood City, California company first launched Udenyca in January. Additional updates are expected to be released on May 9.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

1551807154_andrew.jpg


Register here to be notified of future CHRS Company articles
View full CHRS profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.